Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …

Background There is an extensive literature highlighting the utility of blood-based liquid
biopsies in several extracranial tumors for diagnosis and monitoring. Methods The RANO …

Background The standard of care treatment for muscle-invasive bladder cancer (MIBC) is
radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the …

Studies in multiple solid tumor types have demonstrated the prognostic significance of
ctDNA analysis after curative intent surgery. A combined analysis of data across completed …

Background Identification of residual disease in patients with localized non-small cell lung
cancer (NSCLC) following treatment with curative intent holds promise to identify patients at …